Chronic Idiopathic Myelofibrosis - Pipeline Review, H2 2011

Global Markets Direct, October 2011, Pages: 33

Chronic Idiopathic Myelofibrosis - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Chronic Idiopathic Myelofibrosis - Pipeline Review, H2 2011', provides an overview of the Chronic Idiopathic Myelofibrosis therapeutic pipeline. This report provides information on the therapeutic development for Chronic Idiopathic Myelofibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic Idiopathic Myelofibrosis. 'Chronic Idiopathic Myelofibrosis - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Chronic Idiopathic Myelofibrosis.
- A review of the Chronic Idiopathic Myelofibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Chronic Idiopathic Myelofibrosis pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Chronic Idiopathic Myelofibrosis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Chronic Idiopathic Myelofibrosis pipeline depth and focus of Chronic Idiopathic Myelofibrosis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Chronic Idiopathic Myelofibrosis Overview
Therapeutics Development
An Overview of Pipeline Products for Chronic Idiopathic Myelofibrosis
Chronic Idiopathic Myelofibrosis Therapeutics under Development by Companies
Chronic Idiopathic Myelofibrosis Therapeutics under Investigation by Universities/Institutes
Mid Clinical Stage Products
Comparative Analysis
Chronic Idiopathic Myelofibrosis Therapeutics - Products under Development by Companies
Chronic Idiopathic Myelofibrosis Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Chronic Idiopathic Myelofibrosis Therapeutics Development
S-BIO Pte Ltd
Chronic Idiopathic Myelofibrosis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Pacritinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Busulfan + Cytarabine + Idarubicin + Peripheral Blood Stem Cell Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gleevec - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CEP-701 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lenalidomide + Prednisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Chronic Idiopathic Myelofibrosis Therapeutics – Drug Profile Updates
Chronic Idiopathic Myelofibrosis - Featured News
Jun 13, 2010: S-BIO Reports Positive Results Of SB1518 From Phase I/II Study For the Treatment Of Myelofibrosis
Jun 09, 2010: S-BIO Completes Enrollment In Phase II Clinical Trials For JAK2 Inhibitor SB1518
Apr 19, 2010: YM BioSciences Reports Pre-Publication Of Pivotal Preclinical Data For CYT387
Jan 06, 2009: Onyx Pharmaceuticals Acquires Option to License Novel Highly Specific JAK2 Inhibitors from S-BIO
Dec 02, 2008: S-BIO Advances JAK2 Inhibitor SB1518 into Phase I/II Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• Chronic Idiopathic Myelofibrosis - Pipeline Review, H1 2012
• Chronic Idiopathic Myelofibrosis - Pipeline Review, Q4 2010
• Thrombocythaemia Myelofibrosis - Pipeline Review, H2 2012
• Acquired Orphan Blood Diseases Therapeutics Market to 2019 - Search for Disease Modifying Drugs Central to Unlocking Premium Pricing Potential
• Myelofibrosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019
• Chronic Idiopathic Myelofibrosis - Pipeline Review, Q1 2011
• Thrombocythaemia Myelofibrosis - Pipeline Review, H2 2011
• Post-polycythemia vera myelofibrosis (PPV-MF) - Pipeline Review, H2 2012
• Myelofibrosis Global Clinical Trials Review, H2, 2012
• Thrombocythaemia Myelofibrosis - Pipeline Review, H1 2012